What’s new with GBI Research's Premium Reports under the Pharmaceutical Industry
15 Sep 2011 • by Natalie Aster
Market Publishers Ltd informs that new GBI Research's Pharmaceutical Industry Reports have been added to its catalogue:
The global gastrointestinal disorder therapeutics market is projected to generate revenues of approximately $18.3 billion by 2017, after declining at a CAGR (Compounded Annual Growth Rate) of -4.8% during the period 2010-2017. GBI Research finds that the global gastrointestinal disorder therapeutics market is one of the most mature markets in the pharmaceutical industry. Sales in the market are expected to decline due to various restraints, such as drugs going off-patent, generic substitutions and the availability of alternative therapies. Nevertheless, the global gastrointestinal disorder therapeutics market is an attractive market for the larger pharmaceutical companies.
The global respiratory therapeutics market was valued at $30.1 billion in 2010 and is expected to grow to $37.4 billion by 2017 at a Compound Annual Growth Rate (CAGR) of 3.1%. In 2010, approximately 49 million patients received pharmacological treatment for respiratory disorders with the annual cost of therapy being $611 per year. In addition, the annual cost of therapy for the respiratory disorders therapeutic area is expected to increase at a gradual rate over the following year. The respiratory disorders market growth rate will witness a decline during 2010-2017. This decline can be attributed to the patent expiries of certain branded products such as Tracleer (bosentan), Singulair (montelukast), Symbicort (budesonide and formoterol inhalation), Nasonex (mometasone furoate monohydrate), Rhinocort (budesonide) and Advair (fluticasone and salmeterol).
Published: September’11
Per Report Price:US $3,500.00 (Single User License)
More new market research reports by GBI Research can be found at GBI Research's page
To order the report or ask for sample pages contact [email protected]
Contacts
MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
Analytics & News
